Large-scale testing (Phase 3)Study completedNCT02073279
What this trial is testing
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Who this might be right for
Neuromyelitis Optica (NMO)NMO Spectrum Disorder (NMOSD)
Hoffmann-La Roche 95